Clinical Trial Update: Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial studied the combination of ramucirumab and pembrolizumab in EGFR-mutant recurrent or metastatic non-small cell lung cancer; results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-07-11